Published in Glycobiology on December 07, 2011
Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One (2013) 1.04
Glycodendrimers: tools to explore multivalent galectin-1 interactions. Beilstein J Org Chem (2015) 0.79
Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain. Glycobiology (2016) 0.78
Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR. Glycobiology (2016) 0.76
Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans. J Biol Chem (2016) 0.76
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes. JACC Basic Transl Sci (2016) 0.75
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
NMR View: A computer program for the visualization and analysis of NMR data. J Biomol NMR (1994) 22.42
Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5.30
Galectins: a family of animal beta-galactoside-binding lectins. Cell (1994) 3.99
Apoptosis of T cells mediated by galectin-1. Nature (1995) 3.54
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
Exploring the structural diversity of mammalian carbohydrates ("glycospace") by statistical databank analysis. ACS Chem Biol (2007) 2.42
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med (1997) 1.64
Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds. J Biol Chem (2002) 1.58
Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol (2004) 1.57
Galectin-1 as a potential cancer target. Br J Cancer (2005) 1.45
Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37
Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J Mol Biol (2010) 1.02
Demonstration of protein-protein interaction specificity by NMR chemical shift mapping. Protein Sci (1997) 0.97
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. Biomol NMR Assign (2008) 0.96
The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology (2009) 0.95
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J (2009) 0.94
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res (2009) 0.86
On the galactosyl distribution of commercial galactomannans. Carbohydr Res (2000) 0.84
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res (2003) 1.22
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
Promotion of peptide antimicrobial activity by fatty acid conjugation. Bioconjug Chem (2004) 1.07
Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2004) 1.06
Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. Biochem J (2004) 1.04
Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst (2006) 1.03
Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett (2003) 1.03
CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem (2008) 1.02
Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem (2010) 1.02
Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J Mol Biol (2010) 1.02
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem (2012) 1.00
A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res (2007) 0.98
Metastin (KiSS-1) mimetics identified from peptide structure-activity relationship-derived pharmacophores and directed small molecule database screening. J Med Chem (2007) 0.98
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. Biomol NMR Assign (2008) 0.96
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett (2008) 0.95
The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology (2009) 0.95
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J (2009) 0.94
Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release (2011) 0.92
Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril (2005) 0.91
Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem (2006) 0.90
Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J (2003) 0.89
The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships. J Biol Chem (2004) 0.87
Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem (2007) 0.87
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol (2007) 0.87
Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperthermia (2011) 0.87
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res (2009) 0.86
Structural aspects of binding of α-linked digalactosides to human galectin-1. Glycobiology (2011) 0.86
NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther (2009) 0.85
Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun (2006) 0.84
Heat capacities and a snapshot of the energy landscape in protein GB1 from the pre-denaturation temperature dependence of backbone NH nanosecond fluctuations. J Mol Biol (2003) 0.83
(1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3. Biomol NMR Assign (2014) 0.83
Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis (2003) 0.83
Measuring protein self-diffusion in protein-protein mixtures using a pulsed gradient spin-echo technique with WATERGATE and isotope filtering. J Magn Reson (2004) 0.83
NMR solution structure of the angiostatic peptide anginex. Biochim Biophys Acta (2007) 0.82
Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun (2005) 0.82
Probing structure-activity relationships in bactericidal peptide betapep-25. Biochem J (2008) 0.82
Comparison of (13)C(alpha)H and (15)NH backbone dynamics in protein GB1. Protein Sci (2003) 0.82
Aqueous gel formation of a synthetic peptide derived from the beta-sheet domain of platelet factor-4. Biomacromolecules (2002) 0.81
The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI). Ann Med (2002) 0.79
Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. Glycobiology (2013) 0.79
A simple method to measure 13CH2 heteronuclear dipolar cross-correlation spectral densities. J Magn Reson (2004) 0.79
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin. Biomol NMR Assign (2011) 0.78
p16(INK4a) Peptide mimetics identified via virtual screening. Bioorg Med Chem Lett (2009) 0.78
Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr Pharm Des (2007) 0.77
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs (2013) 0.77
Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery (2004) 0.76
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther (2012) 0.76
Protein dynamics using frequency-dependent order parameters from analysis of NMR relaxation data. J Magn Reson (2003) 0.76
Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis. Chembiochem (2014) 0.76
Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species. Protein Sci (2013) 0.75
Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta (2013) 0.75